查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914567

精準醫療市場－全球產業規模、佔有率、趨勢、機會及預測（依產品/服務、技術、應用、最終用戶、地區及競爭格局分類），2021-2031年

Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Products & Services, By Technology, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球精準醫療市場預計將從 2025 年的 1,183.5 億美元成長到 2031 年的 2,275.4 億美元，複合年成長率達到 11.51%。

這個領域代表了一種疾病預防和治療的創新範式，它提供的醫療保健服務充分考慮了基因、環境和生活方式的個體差異。推動這一市場發展的關鍵因素包括基因測序成本的下降、癌症等複雜慢性疾病的日益增多，以及對副作用較小的標靶治療的需求不斷成長。根據個人化醫療聯盟（Personalized Medicine Coalition）預測，美國食品藥物管理局（FDA）將在2024年核准18種新的個人化藥物，約佔新核准治療性分子實體總數的38%。這項數據印證了該產業正朝著標靶干預的方向發展，與傳統療法相比，標靶干預具有更優的療效。

市場概覽
預測期 2027-2031
市場規模：2025年 1183.5億美元
市場規模：2031年 2275.4億美元
複合年成長率：2026-2031年 11.51%
成長最快的細分市場 生物資訊學
最大的市場 北美洲

然而，該市場面臨與報銷框架和高昂實施成本相關的重大障礙。保險公司和醫療支付者往往難以製定針對這些昂貴治療方法的統一核保政策，這主要是由於難以解讀基因數據和檢驗長期成本效益。因此，診斷測試和後續標靶治療的報銷存在財務不確定性，這嚴重阻礙了精準醫療解決方案在全球醫療體系中的廣泛應用，並可能阻礙其普及。

市場促進因素

次世代定序(NGS) 技術的進步以及由此帶來的基因組分析成本下降是精準醫療市場的關鍵促進因素。這些技術進步已將基因分析從一項高成本的研究活動轉變為常規臨床診斷，從而能夠廣泛檢測出可採取行動的突變。根據 3billion.io 預測，到 2024 年，單一人類基因組的定序成本將降至約 600 美元，這將顯著降低患者和醫療系統的進入門檻。這種成本的降低導致數據生成量激增，為個人化醫療奠定了堅實的基礎。例如，Illumina 公司在 2025 年 6 月報告稱，到 2024 年，其平台平均每分鐘可完成 10 個人類基因定序，這表明可用於指南治療決策的基因組數據規模龐大。

同時，人工智慧與巨量資料分析的融合對於實用化海量遺傳資訊至關重要。隨著基因組和表現型數據的不斷擴展，人工智慧驅動的工具對於解讀複雜數據、識別新型生物標記以及精準預測患者預後至關重要。這種技術協同效應正迅速獲得監管部門的核准，並加速其在臨床上的應用。根據HealthExec報道，截至2025年7月，美國食品藥物管理局（FDA）已核准了1,247總合臨床人工智慧演算法，這標誌著計算診斷領域正發生顯著轉變。監管部門日益成長的認可度正使相關人員能夠部署先進的預測模型，並提高個人化治療的有效性，從而將人工智慧確立為全球精準醫療基礎設施的核心支柱。

市場挑戰

複雜多變的健保報銷環境，加上高昂的實施成本，對全球精準醫療市場的成長構成了重大障礙。醫療服務提供者和支付者往往對昂貴的基因組分析和標靶治療的經濟價值和臨床效用存在分歧，導致醫療保險政策難以預測。這種財務上的不確定性阻礙了醫療機構升級診斷基礎設施，也使製藥研發人員持謹慎態度，擔心他們的創新可能不具備商業性可行性。因此，患者往往需要承擔高額的自付費用，這極大地限制了這些先進醫療解決方案的普及率。

由於缺乏統一的保險覆蓋範圍，市場出現了明顯的碎片化。根據美國癌症協會癌症控制網路統計，截至2024年，美國僅有16個州立法強制要求對生物標記檢測提供全面的保險覆蓋，這意味著該國大部分地區的准入通訊協定有限或尚不明確。這種監管上的不一致性迫使企業在複雜的支付方政策中摸索前行，從而減緩了市場准入速度，並限制了精準醫療技術在全球範圍內的潛在收入。

市場趨勢

液態生物檢體在非侵入性疾病監測中的應用日益廣泛，正推動臨床實踐向頻繁的基於血液的分子監測轉型。這一趨勢在腫瘤學領域尤為明顯，循環腫瘤DNA分析能夠即時追蹤微量殘存疾病。主要診斷機構報告的檢測量快速成長，也反映了該方法的擴充性。根據Natera公司2024會計年度（截至2025年2月）的財務報告，該公司2024年將進行約528,200例腫瘤檢測，較上年成長54.9%。這一快速成長反映出，人們越來越依賴縱向監測，以期比傳統影像學方法更早發現復發。

同時，精準醫療的應用範圍正擴展至中樞神經系統（CNS）疾病，不再侷限於傳統的腫瘤治療領域。這一多元化發展得益於血液生物標記在神經退化性疾病診斷中展現出的顯著療效。這些生物標記為昂貴的PET掃描提供了一種可擴展的替代方案，並有助於篩選適合接受標靶CNS治療的患者。根據Quest Diagnostics公司2025年4月發布的新聞稿，其新型「AD-Detect」血液檢測在2025年美國神經病學會（AAN）年會上發表的研究結果顯示，該檢測在阿茲海默症病理檢測方面達到了91%的敏感度和特異性。如此高的診斷準確率對於精準醫療在神經病學領域的實用化至關重要。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球精準醫療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品/服務分類（精準醫療平台、精準醫療工具、精準醫療服務）
    • 依技術分類（巨量資料分析、人工智慧、生物資訊學、全基因組定序、伴隨診斷、次世代定序、其他）
    • 依應用領域（腫瘤科、心臟科、肺科、神經科、免疫科、其他）
    • 依最終用戶分類（製藥和生物技術公司、醫療保健IT公司、診斷公司、臨床研究機構、研究機構）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲精準醫療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球精準醫療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Illumina
  • Thermo Fisher Scientific
  • Roche
  • Guardant Health
  • Foundation Medicine
  • Qiagen
  • BGI
  • IBM Watson Health
  • Bio-Rad
  • Agilent

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4684

The Global Precision Medicine Market is projected to expand from USD 118.35 Billion in 2025 to USD 227.54 Billion by 2031, achieving a compound annual growth rate of 11.51%. This field represents an innovative paradigm in disease prevention and treatment, tailoring healthcare to account for individual variations in genes, environment, and lifestyle. Key drivers fueling this market include the reduction in genomic sequencing costs, the increasing burden of complex chronic conditions like cancer, and the rising demand for targeted therapies designed to limit adverse drug reactions. According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 18 new personalized medicines in 2024, comprising roughly 38% of all newly approved therapeutic molecular entities, a statistic that underscores the industry's shift toward targeted interventions that offer superior efficacy compared to traditional approaches.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 118.35 Billion
Market Size 2031USD 227.54 Billion
CAGR 2026-203111.51%
Fastest Growing SegmentBioinformatics
Largest MarketNorth America

However, the market faces significant hurdles regarding reimbursement frameworks and the substantial costs associated with implementation. Insurers and healthcare payers often struggle to formulate consistent coverage policies for these premium therapies, largely due to the difficulty of interpreting genetic data and verifying long-term cost-effectiveness. Consequently, the financial uncertainty surrounding reimbursement for both diagnostic testing and subsequent targeted treatments creates a formidable barrier to access, which threatens to impede the broader integration of precision medicine solutions into global healthcare systems.

Market Driver

The evolution of next-generation sequencing (NGS) and the simultaneous decrease in genomic profiling expenses serve as the primary engines driving the precision medicine market. These technological advancements have transitioned genetic analysis from costly research endeavors to routine clinical diagnostics, enabling the widespread detection of actionable mutations. According to 3billion.io, the cost to sequence a human genome dropped to approximately $600 in 2024, significantly lowering entry barriers for patients and healthcare systems alike. This affordability has triggered a surge in data generation, building a strong foundation for personalized care; for instance, Illumina reported in June 2025 that an average of 10 human genomes were sequenced every minute on their platforms throughout 2024, illustrating the massive scale of genomic data available to guide treatment decisions.

In parallel, the integration of artificial intelligence and big data analytics is essential for operationalizing this extensive genetic information. As genomic and phenotypic datasets grow, AI-driven tools have become indispensable for deciphering complex data, identifying novel biomarkers, and accurately predicting patient outcomes. This technological synergy is rapidly achieving regulatory validation, accelerating its clinical adoption. According to HealthExec, by July 2025, the U.S. Food and Drug Administration had cleared a total of 1,247 clinical artificial intelligence algorithms, signaling a definitive move toward computational diagnostics. This increasing regulatory acceptance enables stakeholders to deploy sophisticated predictive models that enhance the efficacy of personalized therapies, establishing AI as a central pillar of the global precision medicine infrastructure.

Market Challenge

The complex and variable landscape of reimbursement, combined with high implementation costs, presents a major obstacle to the growth of the Global Precision Medicine Market. Healthcare providers and payers often disagree on the economic value and clinical utility of expensive genomic profiling and targeted therapies, resulting in unpredictable coverage policies. This financial instability discourages medical institutions from upgrading their diagnostic infrastructure and causes pharmaceutical developers to hesitate, fearing their innovations may lack commercial viability. Consequently, patients frequently encounter prohibitive out-of-pocket costs, which significantly suppresses the adoption rates of these advanced medical solutions.

This absence of uniform coverage creates measurable fragmentation within the market. According to the American Cancer Society Cancer Action Network, in 2024, only 16 U.S. states had enacted legislation mandating comprehensive insurance coverage for biomarker testing, leaving the majority of the country with restricted or undefined access protocols. Such regulatory inconsistency forces companies to navigate a patchwork of payer policies, delaying market entry and limiting the potential revenue scale of precision medicine technologies globally.

Market Trends

The increasing utilization of liquid biopsy for non-invasive disease monitoring is transforming clinical practice toward frequent, blood-based molecular surveillance. This trend is especially impactful in oncology, where circulating tumor DNA analysis allows for the real-time tracking of minimal residual disease. The scalability of this approach is reflected in the rapid volume growth reported by major diagnostic providers; according to Natera's February 2025 financial results for the full year 2024, the company performed approximately 528,200 oncology tests in 2024, representing a 54.9% increase over the prior year. This surge highlights the growing reliance on longitudinal monitoring to detect recurrence earlier than traditional imaging methods allow.

Simultaneously, the scope of precision medicine is expanding into Central Nervous System (CNS) diseases, moving beyond the market's traditional concentration on oncology. This diversification is driven by the validation of blood-based biomarkers for neurodegenerative conditions, which offer scalable alternatives to expensive PET scans and improve patient identification for targeted CNS therapies. According to a press release from Quest Diagnostics in April 2025 regarding their new AD-Detect Blood Test, research presented at the 2025 AAN Annual Meeting showed that the test achieved 91% sensitivity and specificity in detecting Alzheimer's disease pathology. Such diagnostic fidelity is pivotal for operationalizing precision care within the field of neurology.

Key Market Players

  • Illumina
  • Thermo Fisher Scientific
  • Roche
  • Guardant Health
  • Foundation Medicine
  • Qiagen
  • BGI
  • IBM Watson Health
  • Bio-Rad
  • Agilent

Report Scope

In this report, the Global Precision Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Medicine Market, By Products & Services

  • Precision Medicine Platforms
  • Precision Medicine Tools
  • Precision Medicine Services

Precision Medicine Market, By Technology

  • Big Data Analytics
  • Artificial Intelligence
  • Bioinformatics
  • Whole Genome Sequencing
  • Companion Diagnostics
  • NGS
  • Others

Precision Medicine Market, By Application

  • Oncology
  • Cardiology
  • Respiratory
  • Neurology
  • Immunology
  • Others

Precision Medicine Market, By End User

  • Pharmaceutical and Biotechnology Companies
  • Healthcare IT
  • Diagnostic Companies
  • Clinical Research Organization
  • Research Institutes

Precision Medicine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Medicine Market.

Available Customizations:

Global Precision Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Precision Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Products & Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services)
    • 5.2.2. By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, NGS, Others)
    • 5.2.3. By Application (Oncology, Cardiology, Respiratory, Neurology, Immunology, Others)
    • 5.2.4. By End User (Pharmaceutical and Biotechnology Companies, Healthcare IT, Diagnostic Companies, Clinical Research Organization, Research Institutes)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Precision Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Products & Services
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Precision Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Products & Services
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Precision Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Products & Services
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Precision Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Products & Services
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Precision Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Products & Services
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Precision Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Products & Services
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Precision Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Products & Services
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Precision Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Products & Services
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Precision Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Products & Services
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Precision Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Products & Services
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Precision Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Products & Services
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Precision Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Products & Services
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Precision Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Products & Services
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Precision Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Products & Services
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Precision Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Products & Services
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Precision Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Products & Services
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Precision Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Products & Services
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Precision Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Products & Services
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Precision Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Products & Services
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Precision Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Products & Services
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Precision Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Products & Services
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Precision Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Products & Services
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Precision Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Products & Services
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Precision Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Products & Services
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Precision Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Illumina
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific
  • 15.3. Roche
  • 15.4. Guardant Health
  • 15.5. Foundation Medicine
  • 15.6. Qiagen
  • 15.7. BGI
  • 15.8. IBM Watson Health
  • 15.9. Bio-Rad
  • 15.10. Agilent

16. Strategic Recommendations

17. About Us & Disclaimer